Shockwave Medical, Inc.: insider trades · United States · SEC (Form 4)

About Shockwave Medical, Inc.

Shockwave Medical, Inc. is a U.S. medical device company focused on treating calcified cardiovascular disease through intravascular lithotripsy (IVL), a technology that uses acoustic pressure waves to fracture calcium inside arterial walls. The company was founded in 2009 by a team spanning marketing, engineering, and cardiology, with the original goal of adapting the well-known kidney-stone lithotripsy concept to vascular intervention. Its corporate headquarters are in Santa Clara, California, United States. Shockwave was historically listed on the NASDAQ under the ticker SWAV and became a widely recognized name in the cardiovascular medtech universe before being acquired by Johnson & Johnson; the transaction closed on May 31, 2024. For market readers, that is the key context: SWAV is no longer a stand-alone public equity, but its operating legacy remains highly relevant in the U.S. listed medtech landscape. At the business level, Shockwave built its franchise around IVL systems for coronary and peripheral artery disease, targeting heavily calcified lesions that can be difficult to treat with conventional balloon angioplasty alone. Its product portfolio includes coronary and peripheral catheter platforms designed to modify calcium in a predictable, low-pressure way before definitive vessel therapy. The company’s competitive positioning was driven by first-mover advantage, a strong clinical evidence base, and a differentiated mechanism of action that resonated with interventional cardiologists and vascular specialists. In practical terms, Shockwave established itself as a category leader in calcium modification, where procedural success, safety, and operator simplicity are crucial adoption factors. Geographically, Shockwave developed a commercial footprint in the United States and abroad, including distribution and support across multiple European markets. That international presence mattered because adoption of IVL required both clinical education and regulatory execution across different health systems. A major recent milestone was the May 2024 acquisition by Johnson & Johnson, which SEC filings and J&J’s annual reporting confirm and which moved Shockwave into J&J’s Cardiovascular franchise. From an investor’s perspective, this matters for three reasons: it validated the strategic value of the platform, it ended SWAV’s standalone public-market life, and it repositioned the business inside one of the world’s largest medtech groups. Overall, Shockwave Medical should be viewed as a pioneering U.S. medtech innovator whose core asset was its IVL technology and whose market significance was ultimately recognized through acquisition by a global healthcare leader.